Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator ( CFTR) Translation Product*

被引:70
作者
Haggie, Peter M. [1 ,2 ]
Phuan, Puay-Wah [1 ,2 ]
Tan, Joseph-Anthony [1 ,2 ]
Xu, Haijin [5 ]
Avramescu, Radu G. [5 ]
Perdomo, Doranda [5 ]
Zlock, Lorna [3 ]
Nielson, Dennis W. [4 ]
Finkbeiner, Walter E. [3 ]
Lukacs, Gergely L. [5 ]
Verkman, Alan S. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[5] McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada
基金
美国国家卫生研究院;
关键词
MESSENGER-RNA DECAY; CYSTIC-FIBROSIS; CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; NONSENSE MUTATIONS; ROCK INHIBITOR; BIOAVAILABILITY; DOMAIN; TERMINATION; RESTORATION;
D O I
10.1074/jbc.M116.764720
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
W1282X is the fifth most common cystic fibrosis transmembrane regulator (CFTR) mutation that causes cystic fibrosis. Here, we investigated the utility of a small molecule corrector/potentiator strategy, as used for Delta F508-CFTR, to produce functional rescue of the truncated translation product of the W1282X mutation, CFTR1281, without the need for readthrough. In transfected cell systems, certain potentiators and correctors, including VX-809 and VX-770, increased CFTR1281 activity. To identify novel correctors and potentiators with potentially greater efficacy on CFTR1281, functional screens were done of similar to 30,000 synthetic small molecules and drugs/nutraceuticals in CFTR1281-transfected cells. Corrector scaffolds of 1-arylpyrazole-4-arylsulfonyl-piperazine and spiro-piperidine-quinazolinone classes were identified with up to similar to 5-fold greater efficacy than VX-809, some of which were selective for CFTR1281, whereas others also corrected Delta F508-CFTR. Several novel potentiator scaffolds were identified with efficacy comparable with VX-770; remarkably, a phenylsulfonamide-pyrrolopyridine acted synergistically with VX-770 to increaseCFTR(1281) function similar to 8-fold over that of VX-770 alone, normalizing CFTR1281 channel activity to that of wild type CFTR. Corrector and potentiator combinations were tested in primary cultures and conditionally reprogrammed cells generated from nasal brushings from one W1282X homozygous subject. Although robust chloride conductance was seen with correctors and potentiators in homozygous Delta F508 cells, increased chloride conductance was not found in W1282X cells despite the presence of adequate transcript levels. Notwithstanding the negative data inW1282Xcells from one human subject, we speculate that corrector and potentiator combinations may have therapeutic efficacy in cystic fibrosis caused by the W1282X mutation, although additional studies are needed on human cells from W1282X subjects.
引用
收藏
页码:771 / 785
页数:15
相关论文
共 53 条
[1]   Bioavailability of curcumin: Problems and promises [J].
Anand, Preetha ;
Kunnumakkara, Ajaikumar B. ;
Newman, Robert A. ;
Aggarwal, Bharat B. .
MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818
[2]   New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays [J].
Baell, Jonathan B. ;
Holloway, Georgina A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2719-2740
[3]   The role of the C terminus and Na+/H+ exchanger regulatory factor in the functional expression of cystic fibrosis transmembrane conductance regulator in nonpolarized cells and epithelia [J].
Benharouga, M ;
Sharma, M ;
So, J ;
Haardt, M ;
Drzymala, L ;
Popov, M ;
Schwapach, B ;
Grinstein, S ;
Du, K ;
Lukacs, GL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (24) :22079-22089
[4]  
Bowden JPB., 2014, Patent, Patent No. [WO02014167530A1, 02014167530, 2014167530 A1, 2014167530]
[5]   Domain interdependence in the biosynthetic assembly of CFTR [J].
Cui, Liying ;
Aleksandrov, Luba ;
Chang, Xiu-Bao ;
Hou, Yue-Xian ;
He, Lihua ;
Hegedus, Tamas ;
Gentzsch, Martina ;
Aleksandrov, Andrei ;
Balch, William E. ;
Riordan, John R. .
JOURNAL OF MOLECULAR BIOLOGY, 2007, 365 (04) :981-994
[6]   Cystic fibrosis genetics: from molecular understanding to clinical application [J].
Cutting, Garry R. .
NATURE REVIEWS GENETICS, 2015, 16 (01) :45-56
[7]   The future of CFTR modulating therapies for cystic fibrosis [J].
Davies, Jane C. .
CURRENT OPINION IN PULMONARY MEDICINE, 2015, 21 (06) :579-584
[8]   Cooperative Assembly and Misfolding of CFTR Domains In Vivo [J].
Du, Kai ;
Lukacs, Gergely L. .
MOLECULAR BIOLOGY OF THE CELL, 2009, 20 (07) :1903-1915
[9]   PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model [J].
Du, Ming ;
Liu, Xiaoli ;
Welch, Ellen M. ;
Hirawat, Samit ;
Peltz, Stuart W. ;
Bedwell, David M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) :2064-2069
[10]   Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o- [J].
Ehrhardt, C ;
Collnot, EM ;
Baldes, C ;
Becker, U ;
Laue, M ;
Kim, KJ ;
Lehr, CM .
CELL AND TISSUE RESEARCH, 2006, 323 (03) :405-415